Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2015-03-04Clinical Trial Update: Impact of Dance Therapy on Parkinson's Disease [NA]
A clinical trial evaluating dance therapy for Parkinson's disease has been withdrawn; the study status is withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-01-08Clinical Trial Update: Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235) [Phase 1]
A Phase 1 single-dose pharmacokinetics study of SCH 900800 in Parkinson's disease patients treated with L-DOPA was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-08-08Clinical Trial Update: Electrophysiological Investigation and rTMS Intervention of Ambulatory Central Processing of Freezing of Gait in Parkinson's Disease [NA]
The clinical trial evaluating electrophysiological aspects and rTMS treatment for freezing of gait in Parkinson's disease has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2014-07-01Clinical Trial Update: Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating dexmedetomidine during deep brain stimulation for Parkinson's disease, essential tremor, and dystonia …
-
CLINICAL_TRIALS withdrawal · 2014-02-20Clinical Trial Update: Optimizing DBS Electrode Placement and Programming
A clinical trial evaluating DBS electrode placement and programming for Parkinson's disease and essential tremor has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2013-10-31Clinical Trial Update: The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations [Phase 2]
A Phase 2 clinical trial evaluating E2007 to alter pharmacodynamic responses to Levodopa in patients with Parkinson's disease and dyskinesia…
-
CLINICAL_TRIALS withdrawal · 2013-03-29Clinical Trial Update: Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating droxidopa for freezing of gait in Parkinson's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-03Clinical Trial Update: Use of Zolpidem in Parkinson's Disease [Phase 2]
A Phase 2 clinical trial investigating Zolpidem for Parkinson's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-03Clinical Trial Update: Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease [Phase 4]
A Phase 4 clinical trial evaluating solifenacin succinate (VESICARE) for urinary incontinence in Parkinson's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-11-06Clinical Trial Update: Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon [NA]
The ramelteon trial for sleep/wake disturbances in basal ganglia disorders has been withdrawn, involving Huntington's disease and Parkinson'…
-
EMA withdrawal · 2012-09-27EMA Withdrawn: Rivastigmine Teva (rivastigmine) — Teva Pharma B.V.
The EMA withdrew Rivastigmine Teva (rivastigmine) from its European market authorization.
-
CLINICAL_TRIALS withdrawal · 2012-04-30Clinical Trial Update: Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off [Phase 4]
A Phase 4 trial comparing carbidopa/levodopa with and without entacapone in Parkinson's disease was withdrawn; no results are available.
-
CLINICAL_TRIALS withdrawal · 2011-02-18Clinical Trial Update: Feasibility Study to Evaluate Deep Brain Stimulation (DBS) Settings for the Treatment of Parkinson's Disease [NA]
A feasibility study evaluating deep brain stimulation settings for Parkinson's disease was withdrawn; the trial sponsor was Intelect Medical…
-
EMA withdrawal · 2009-03-10Orion Corporation withdraws its application for an extension of indication for Stalevo (levodopa/carbidopa/entacapone)
Orion Corporation has withdrawn its application to extend the indication for Stalevo (levodopa/carbidopa/entacapone).
-
EMA withdrawal · 2006-05-23EMA Withdrawn: Daquiran (pramipexole dihydrochloride monohydrate) — Dr. Karl Thomae GmbH
EMA withdrew Daquiran (pramipexole dihydrochloride monohydrate) from the market; Parkinson's disease was the therapeutic area.